Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer.

Abstract

There were 21 patients with advanced, measurable bladder cancer who were treated with cis-diamminedichloride platinum II. Of the 21 patients 3 (14 per cent) achieved a complete response that persisted for more than 1 year, while 6 (29 per cent) achieved a partial remission for an average duration of 5.7 months. Responses to cis-diamminedichloride platinum II were noted shortly after administration of the drug. After the initial response no additional benefit of cis-diamminedichloride platinum II was observed after 9 weeks (third dose). Despite the fact that cis-diamminedichloride platinum II was tolerated reasonably well by the majority of patients and that there were 3 cases of long-term remission cis-diamminedichloride platinum II appears limited to induction of a response in patients with advanced bladder cancer rather than for long-term maintenance therapy.

• Authors: H W Herr
• Journal: The Journal of urology (J Urol) Vol. 123 Issue 6 Pg. 853-5 (Jun 1980) ISSN: 0022-5347 [Print] United States
• PMID: 7189792 (Publication Type: Journal Article)

Chemical References

• Cisplatin

Topics

• Aged
• Cisplatin (therapeutic use, toxicity)
• Female
• Humans
• Male
• Middle Aged
• Urinary Bladder Neoplasms (drug therapy, mortality)